Overcoming PROTAC Resistance: Identifying Structural and Genomic Predictors of Efficacy in Next-Generation Targeted Protein Degraders for Hard-to-Treat Cancers
- May 29
- 2 min read
Original Research | 2026 | Volume 3 | Issue 4 | Page 34-39
Dr. Shahan Layek, Independent Researcher, West Bengal, India, Email: layekcallmeshahan@gmail.com
Abstract:
Proteolysis-Targeting Chimeras (PROTACs) have emerged as a revolutionary modality in chemical biology, offering the ability to degrade "undruggable" proteins by hijacking the cell's ubiquitin-proteasome system. Despite their clinical promise, the acquisition of resistance—arising from mutations in the degradation machinery, altered stoichiometry of the E3 ligase complex, and compensatory signaling pathways—poses a significant barrier to their long-term efficacy. This study investigates the structural and genomic determinants of PROTAC resistance, aiming to identify predictive biomarkers that can guide the development of next-generation degraders for recalcitrant cancers. Through an integrated approach utilizing CRISPR-Cas9 genome-wide screens and structural modeling of ternary complex formation, we characterized the landscape of resistance across diverse cancer cell lines. Our data reveal that resistance is not merely a consequence of target protein mutation but is frequently driven by the downregulation of essential E3 ligase components and the upregulation of deubiquitinating enzymes (DUBs) that stabilize the target protein. Furthermore, we identified critical structural vulnerabilities in the PROTAC molecule—specifically linker length and rigidity—that correlate with successful ternary complex formation and resistance evasion. Our findings demonstrate that PROTACs incorporating optimized E3 ligase recruiters and stabilized linker architectures maintain high degradative efficiency even in the presence of established resistance mutations. Additionally, we developed a genomic signature that predicts patient sensitivity to specific PROTAC classes, providing a framework for precision therapeutic selection. These insights highlight the importance of designing "resistance-proof" degraders by leveraging structural biology to optimize the ternary complex and applying genomic diagnostics to personalize treatment. This study provides a foundational roadmap for the next generation of PROTACs, shifting the paradigm from broad-spectrum degradation to highly selective, durable, and resistance-resilient protein knockdown in hard-to-treat malignancies.